Thirty-two products recently have had label changes to the boxed warnings, contraindications, and warnings sections, according to the FDA.
Thirty-two products recently have had label changes to the boxed warnings, contraindications, and warnings sections, according to FDA.
The FDA MedWatch July 2011 Safety Labeling Changes posting included the following products:
Epogen/Procrit (epoetin alfa) and Aranesp (darbepoetin alfa)
Dostinex (cabergoline) Tablets
Nitrostat (nitroglycerin, USP) Sublingual Tablets
Paxil (paroxetine HCl) tablets, oral solution, and Paxil CR tablets
Ranexa (Ranolazine) Extended-Release Tablets
Rotavirus Vaccine, Live, Oral, Pentavalent (RotaTeq)
Arava (leflunomide) Tablets
Bentyl (dicyclomine hydrochloride, USP) Capsules/Tablets, Oral Syrup, Injection
Chantix (varenicline) Tablets
Flomax (tamsulosin hydrochloride) Capsules
Gilenya (fingolimod) capsules 0.5 mg
Kenalog-10 (triamcinolone acetonide) Injection, Kenalog-40 (triamcinolone acetonide) Injection
Micardis (telmisartan) Tablets
Prograf (tacrolimus) Capsules, Injection
Seroquel (quetiapine fumarate) Tablets, Seroquel (quetiapine fumarate) XR
Tev-Tropin (somatropin [rDNA origin]) for injection
Truvada (emtricitabine/tenofovir disoproxil fumarate) tablets
Zegerid OTC (omeprazole 20mg and sodium bicarbonate 1100 mg) capsules
“FDA’s just-released series of updates and/or changes for safety labeling
purposes on 32 products primarily catches them up on what has been known for
a while in the marketplace,”said Randy Vogenberg, PhD, principal at the Institute for Integrated Healthcare in Sharon, Mass., and executive director of the Biologic Access & Finance program at The Jefferson School of Population Health in Philadelphia.
“Changes to patient information. . .will better inform the patient of potential issues to watch for or report to their clinician or pharmacist,” said Vogenberg, who is the author of Pharmacy Benefits: Management and Benefit Design, published by IFEBP.
For a more detailed listing of drug names and revised safety labeling sections go to:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm266122.htm
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.